A Method for Estimating Progression Rates in Alzheimer Disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The ability to predict progression of disease in patients with Alzheimer disease (AD) would aid clinicians, improve the validation of biomarkers, and contribute to alternative study designs for AD therapies. OBJECTIVE: To test a calculated rate of initial decline prior to the first physician visit (preprogression rate) for its ability to predict progression during subsequent follow-up. METHODS: We calculated preprogression rates for 298 patients with probable or possible AD (using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA) with a formula using expected Mini-Mental State Examination (MMSE) scores, scores at presentation, and a standardized estimate of duration. The patients are being followed up longitudinally in our Alzheimer Disease Research Center. The time to clinically meaningful deterioration, defined as an MMSE score drop of 5 or more points, was compared for patients stratified as slow, intermediate, and rapid progressors based on the preprogression rate. Cox regression analysis was used to examine the contribution of demographic variables (age, sex, ethnicity, and level of education), initial MMSE scores, estimated symptom duration, and the calculated preprogression rate to the time it took to reach the end point across the groups. RESULTS: Both initial MMSE (hazard ratio, 0.95 (0.002); z = 4.19; P<.001) and the calculated preprogression rate (hazard ratio, 1.06 (0.019); z = 3.16; P =.002) were significant in determining time to clinically meaningful decline during longitudinal follow-up (Cox regression analysis). Slow, intermediate, and rapid progressors (based on preprogression rates) experienced significantly different time intervals to clinically meaningful deterioration, with the slow progressors taking the longest time, the intermediate progressors in the middle, and the rapid progressors reaching the end point first (log rank chi(2)(1) = 9.81, P =.002). CONCLUSION: An easily calculable rate of early disease progression can classify patients as rapid, intermediate, or slow progressors with good predictive value, even at initial presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Predicting Time to Nursing Home Care and Death in Individuals With Alzheimer Disease
Stern, Y. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340040030 · Cited by 359 · cited 1×
“Others have suggested that the initial stage of disease at the beginning of the observation period (“how far”) is an important predictor of subsequent decline (“how fast”).(3,4) Most staging measures fail to document linear decline over the course of AD,(5,6) and as a result both “bilinear”(7) and “trilinear”(8,9) mod…”
BackgroundJacobs, D., Sano, M., Marder, K., Bell, K., Bylsma, F., Lafleche, G., Albert, M., Brandt, J., & Stern, Y. (1994) · Neurology · doi:10.1212/wnl.44.7.1215 · Cited by 266
Cited by
Survival after Initial Diagnosis of Alzheimer Disease
Larson, E. B., Shadlen, M.-F., Wang, L., McCormick, W. C., Bowen, J. D., Teri, L., & Kukull, W. A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00008 · Cited by 543
Delirium accelerates cognitive decline in Alzheimer disease
Fong, T. G., Jones, R. N., Shi, P., Marcantonio, E. R., Yap, L., Rudolph, J. L., Yang, F. M., Kiely, D. K., & Inouye, S. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a4129a · Cited by 495
Sloane, P. D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., & Sudha, S. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140525 · Cited by 461
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Lam, B., Masellis, M., Freedman, M., Stuss, D. T., & Black, S. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt155 · Cited by 386
“More generally, as it appears that all AD subtypes exhibit divergent trajectories of symptom progression from prototypic disease, characterizing the onset and decline across the AD syndrome spectrum [89,90], including comorbid cases, is a priority.”
BackgroundBrodaty, H., Seeher, K., & Gibson, L. (2012) · International Psychogeriatrics · doi:10.1017/s1041610211002924 · Cited by 248
Metadata
- Authors
- Doody, R. S., Massman, P., & Dunn, J. K.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2001-03-01
- Volume
- 58
- Issue
- 3
- Pages
- 449-54
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2003919893
- Cited by
- 194
- References
- 3
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.